Navigation Links
Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
Date:6/6/2008

Company to Continue Focus on Pipeline and Haptoglobin Diagnostic Assay

MONTVALE, N.J., June 6 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) today announced data from three Phase 2 trials (Trials 201a, 201 and 203) of SYI-2074 in Type 2 diabetic patients. Trial 201a established that haptoglobin (Hp) types, the target of Synvista's proprietary haptoglobin variant test currently under development, correlated with a difference in baseline levels of plasma isoprostanes, confirming that Hp2-2 in diabetic patients is associated with increased oxidized lipids. The mean F2a isoprostane level in Hp2-2 diabetic patients was 632 ng/mg Cr and in Hp1-1 diabetic patients was 453 ng/mg Cr (p=0.001). Trial 201 showed that SYI-2074, in Hp2-2 diabetic patients, did not demonstrate a dose-related improvement in all oxidized lipids and all markers of oxidative stress after one month. In Trial 203, SYI-2074 did not provide evidence of protection against cardiac injury in diabetic patients who were undergoing angioplasty. The Company has therefore decided not to advance the development of SYI-2074 as a treatment for acute coronary syndrome, while it continues to review and analyze the results of these studies.

These Phase 2 results do not impact the Company's plans to test a topical formulation of SYI-2074 in plaque psoriasis. Synvista expects to begin enrollment of patients with mild-to-moderate plaque psoriasis in a Phase 2 trial in the third quarter of 2008, as originally planned. The Company is continuing to evaluate a series of back-up compounds to SYI-2074 in preclinical studies, on the basis of some of the signals in these trials. The Company hopes to provide an update on this program during the third quarter of 2008.


'/>"/>
SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
2. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
3. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
4. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
5. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
6. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
7. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
8. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
9. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
10. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
11. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life ... total revenues of $39.8 million for the second quarter ... of $24.5 million for the second quarter of 2013. ... sold on May 30, 2014, has been accounted for ... been excluded from continuing operations for all periods. ...
(Date:7/29/2014)... July 29, 2014 Pfenex Inc. (NYSE MKT: PFNX) ... public offering of 8,333,333 shares of its common  stock at ... of the common stock was offered by Pfenex. In addition, ... up to 1,250,000 additional shares of common stock at the ... traded on the NYSE MKT under the symbol "PFNX." ...
(Date:7/29/2014)... 29, 2014  EnteroMedics Inc. (NASDAQ: ETRM ... to treat obesity, metabolic diseases and other gastrointestinal disorders, ... on Thursday, August 7, 2014 at 11:00 AM Eastern ... ended June 30, 2014 and to provide a business ... second quarter conference call may be accessed by dialing ...
Breaking Medicine Technology:Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 2Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 3Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 4Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 6Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 7Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 8Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 9Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 10Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 11Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 12Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 13Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 14Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 15Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 16Pfenex Announces Closing of Initial Public Offering 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3
... 2011 A west coast secret is finally reaching the ... from Beverly Hills, California, a health and beauty boutique named ... ).  A clinically tested dietary supplement is helping thousands of ... than 4 weeks of use.  Just a few capsules per ...
... SAN DIEGO, Sept. 29, 2011 Awarepoint ... system (RTLS) solutions for healthcare, announced today that ... (RFID) and RTLS Healthcare Competitive Strategy Leadership ... pioneering and providing complete RTLS and workflow automation ...
Cached Medicine Technology:Beverly Hills Secret Now Helping People Across The Country 2Awarepoint Corporation Receives Frost & Sullivan's 2011 North American RFID and RTLS Healthcare Competitive Strategy Leadership Award 2Awarepoint Corporation Receives Frost & Sullivan's 2011 North American RFID and RTLS Healthcare Competitive Strategy Leadership Award 3
(Date:7/29/2014)... -- Although the bite of a brown recluse spider ... alone, an expert notes. It,s still important to ... a brown recluse spider bite, warned Dr. Donna Seger, ... these potentially dangerous bites are on the rise. ... nothing. The [bite] has classic characteristics, but if physicians ...
(Date:7/29/2014)... Using quality improvement measures in eight of the ... Study Group, researchers have found a way to reduce ... dye. , Currently, 7-15 percent of these patients who ... with kidney injury, which can result in death or ... permanent dialysis, says a study published in the July ...
(Date:7/29/2014)... 29, 2014 New high priced hepatitis ... D by a projected $2.9 to $5.8 billion next ... firm Milliman released today by the Pharmaceutical Care Management ... could increase by as much as 8.6 percent in ... including Sovaldi and Olysio. , The study finds that ...
(Date:7/29/2014)... Alto, CA (PRWEB) July 29, 2014 ... and well-being in older adults. Once again, the non-profit agency ... Celebration, a free event for seniors. , This event gives ... active and maintain better health. There will be a variety ... and dancing, wellness vendors, tech demonstrations and artists. In addition, ...
(Date:7/29/2014)... donor kidney transplants receive steady follow-up care, the ... To make follow-up care more accessible, UC San ... collaborating to launch the first program in the ... charge to living kidney donors. , UCSF will ... more than 4,500 Walgreens pharmacies and Healthcare Clinic ...
Breaking Medicine News(10 mins):Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2Health News:Reducing kidney injury using a quality improvement method 2Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:Avenidas Hosts Third Annual Successful Aging Celebration 2Health News:Caring for donors 2Health News:Caring for donors 3
... Web site,s c ontent is ... CHICAGO, July 15 In an emergency, immediate access to ... death. Personal health records (PHRs) often help ease the tension and ... encounters. To increase its PHR public outreach, the American Health Information ...
... , Goodman: Bill Contains All the Bad ... DALLAS, July 15 The Democrats, health care reform bill currently ... health plan that will undercut the private market and force as many ... forced into a Medicare-like plan, according to National Center for Policy Analysis ...
... , Dr. Thomas Bryant Brings Hill ... WASHINGTON, July 15 The National Coalition of Mental ... Bryant, MD, JD, as its first-ever Director of Government Relations. Dr. ... excited to join the staff of the National Coalition. The most ...
... HMSY ) today announced it will host a webcast and conference call at 9:00 am ET on ... which ended June 30. Financial results are scheduled for release before the market opens on Friday, ... William Lucia, CEO, Walter Hosp, CFO, ... 9:00 AM ET, , , HOW: Presentation: , ...
... , , American Society of ... s Water and Wastewater Infrastructure Systems , ... owe our health and much of our quality of life to the ... water and wastewater systems on which we rely. Despite the importance of ...
... , BETHESDA, Md., July 15 ... solutions, today announced the release of the PatientLife System(R) 3.5 (PLS ... focused on accelerating the discharge planning process and reducing average length ... , "We are excited about the new functionality of ...
Cached Medicine News:Health News:AHIMA Launches New Interactive myPHR.com Web Site 2Health News:AHIMA Launches New Interactive myPHR.com Web Site 3Health News:House Democrat's Health Care Reform Bill Is a 1,018-Page Nightmare 2Health News:National Coalition of Mental Health Consumer/Survivor Organizations Hires Director of Government Relations 2Health News:HMS Holdings Corp. Hosts Second Quarter 2009 Financial Teleconference and Presentation 2Health News:Proposed Water Trust Fund Bill Would Provide Solid Foundation for Improvement 2Health News:GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 2Health News:GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 3Health News:GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 4
BD Visitec IOL Manipulator (Sinskey), blunt tip angled 45, 15.0 mm from end, fits 0.20 mm diameter holes and larger (3/bx, 1 bx/ca), sterile. For positioning intraocular lenses. Sure grip handles han...
... BD Visitec IOL Manipulator (Jaffe-Maltzman), ... mm from end, fits 0.20 ... for positioning intraocular lenses, (3/bx, ... intraocular lenses. Sure grip handles ...
Maltzman-Fenzl lens manipulator, V shaped tip, straight. Also available in titanium....
Sinskey lens manipulator, straight. Also available in titanium....
Medicine Products: